Download PDF
Z Gastroenterol 2015; 53(10): 1187-1192
DOI: 10.1055/s-0035-1553477
Kasuistik
© Georg Thieme Verlag KG Stuttgart · New York

Morbus Behçet oder chronisch-entzündliche Darmerkrankung – ein diagnostisches und therapeutisches Dilemma

Morbus Behçet or inflammatory bowel disease – a diagnostic and therapeutic dilemma
S. Schack
1   Gastroenterologie, Hepatologie und Infektologie, Friedrich-Schiller-Universität, Jena, Germany
,
M. Weber
1   Gastroenterologie, Hepatologie und Infektologie, Friedrich-Schiller-Universität, Jena, Germany
,
P. Oelzner
2   Nephrologie, Rheumatologie und Diabetologie, Friedrich-Schiller-Universität, Jena, Germany
,
M. Mireskandari
3   Institut für Pathologie, Friedrich-Schiller-Universität, Jena, Germany
,
D. Antonov
4   Klinik für Hautkrankheiten, Friedrich-Schiller-Universität, Jena, Germany
,
A. Stallmach
1   Gastroenterologie, Hepatologie und Infektologie, Friedrich-Schiller-Universität, Jena, Germany
› Author Affiliations
Further Information

Publication History

30 April 2015

15 July 2015

Publication Date:
19 October 2015 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Wir berichten über einen 43-jährigen kaukasischen Mann mit einer initial als Colitis ulcerosa eingeordneten Erkrankung. Während des 2-jährigen Krankheitsverlaufs wurden mit nur geringem Erfolg und z. T. schwerwiegenden Komplikationen Azathioprin und anti-TNF-alpha-Antikörper eingesetzt. Bei Auftreten einer komplexen Begleitsymptomatik aus oralen und skrotalen Ulzerationen, Arthritiden und verletzungsassoziierten Hautläsionen wurde erstmals die Differenzialdiagnose eines Morbus Adamantiades-Behçet mit intestinaler Beteiligung erwogen. Nach Einleitung einer parenteralen Ciclosporingabe und im Verlauf Umstellung auf Tacrolimus und Azathioprin konnte eine mehrmonatige Remission erreicht werden. Ein therapieassoziiertes akutes Nierenversagen machte schließlich die Einstellung auf Golimumab notwendig, unter der sich zunächst eine verzögerte, dann jedoch deutliche Befundbesserung einstellte.

Die Abgrenzung des Morbus Adamantiades-Behçet von CED mit extraintestinalen Manifestationen ist von besonderer Schwierigkeit, bedarf der interdisziplinären Zusammenarbeit und ist letztlich die Voraussetzung für eine erfolgreiche Therapie.

Abstract

We present the case of a 43-year old caucasian male suffering from a condition initially diagnosed as colitis ulcerosa. For 2 years Azathioprine and anti-TNF-alpha antibodies were used for treatment without convincing benefit but with serious adverse events. After the first occurrence of complex accompanying symptoms like oral and scrotal ulcerations, arthritis and scratch-induced skin lesions the differential diagnosis of a Morbus Adamantiades-Behçet with intestinal evolvement was considered. After introduction of a parenteral Ciclosporin medication, which was later switched to Tacrolimus and Azathioprin, a remission could be achieved that lasted for several months. When a drug-induced acute kidney injury occurred, the regime was changed to Golimumab and a delayed but significant improvement was achieved.

To separate Morbus Adamantiades-Behçet from inflammatory bowel disease is of some difficulty, demands interdisciplinary cooperation and is the basis for a successful therapy.

Schlüsselwörter

Chronisch-entzündliche Darmerkrankung - chronische gastrointestinale Blutung - Morbus Crohn

Key words

inflammatory bowel disease - chronic intestinal bleeding - Crohn’s disease
 

  • Literatur

  • 1 Kurtzman DJ, Jones T, Lian F et al. Metastatic Crohn’s disease: a review and approach to therapy. Journal of the American Academy of Dermatology 2014; 71: 804-813
    CrossrefPubMedGoogle Scholar
  • 2 Altenburg A, Mahr A, Maldini C et al. Epidemiology and clinical aspects of Adamantiades-Behcet disease in Gemany. Current data. Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2012; 109: 531-541
    CrossrefPubMedGoogle Scholar
  • 3 Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A et al. Colchicine versus placebo in Behcet's disease: randomized, double-blind, controlled crossover trial. Modern rheumatology/the Japan Rheumatism Association 2009; 19: 542-549
    PubMedGoogle Scholar
  • 4 Melikoglu M, Fresko I, Mat C et al. Short-term trial of etanercept in Behcet’s disease: a double blind, placebo controlled study. The Journal of Rheumatology 2005; 32: 98-105
    PubMedGoogle Scholar
  • 5 Saenz A, Ausejo M, Shea B et al. Pharmacotherapy for Behcet’s syndrome. The Cochrane database of systematic reviews 2000; DOI: 10.1002/14651858.CD001084. CD001084
    PubMedGoogle Scholar
  • 6 Kotter I, Gunaydin I, Zierhut M et al. The use of interferon alpha in Behcet disease: review of the literature. Seminars in Arthritis and Rheumatism 2004; 33: 320-335
    CrossrefPubMedGoogle Scholar
  • 7 Lee JH, Cheon JH, Jeon SW et al. Efficacy of infliximab in intestinal Behcet’s disease: a Korean multicenter retrospective study. Inflammatory Bowel Diseases 2013; 19: 1833-1838
    PubMedGoogle Scholar
  • 8 Diaz-Llopis M, Cervera M, Menezo JL. Cyclosporin A treatment of Behcet’s disease: a long-term study. Current eye research 1990; 9: 17-23
    CrossrefPubMedGoogle Scholar
  • 9 Hatemi G, Silman A, Bang D et al. Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease. Annals of the Rheumatic Diseases 2009; 68: 1528-1534
    CrossrefPubMedGoogle Scholar
  • 10 Yazici H, Pazarli H, Barnes CG et al. A controlled trial of azathioprine in Behcet’s syndrome. The New England Journal of Medicine 1990; 322: 281-285
    CrossrefPubMedGoogle Scholar
  • 11 Evereklioglu C. Current concepts in the etiology and treatment of Behcet disease. Survey of ophthalmology 2005; 50: 297-350
    CrossrefPubMedGoogle Scholar
  • 12 Grigg EL, Kane S, Katz S. Mimicry and deception in inflammatory bowel disease and intestinal behcet disease. Gastroenterology & Hepatology 2012; 8: 103-112
    PubMedGoogle Scholar
  • 13 International Team for the Revision of the International Criteria for Behcet’s D. The International Criteria for Behcet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. Journal of the European Academy of Dermatology and Venereology: JEADV 2014; 28: 338-347
    CrossrefPubMedGoogle Scholar
  • 14 Glosemeyer R, Deppe H, Dormann AJ et al. Ulcerative esophagitis and colitis as rare manifestations of Adamantiades-Behcet disease. Zeitschrift für Gastroenterologie 2001; 39: 167-171
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Lee SK, Kim BK, Kim TI et al. Differential diagnosis of intestinal Behcet’s disease and Crohn’s disease by colonoscopic findings. Endoscopy 2009; 41: 9-16
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Bernstein CN, Blanchard JF, Rawsthorne P et al. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. The American Journal of Gastroenterology 2001; 96: 1116-1122
    CrossrefPubMedGoogle Scholar
  • 17 Reinshagen M, Fölsch UR. Extraintestinale Manifestationen bei Colitis ulcerosa. Zeitschrift fur Gastroenterologie 2004; 42: 1024-1028
    PubMedGoogle Scholar
  • 18 Yokota K, Hayashi S, Fujii N et al. Antibody response to oral streptococci in Behcet’s disease. Microbiology and Immunology 1992; 36: 815-822
    CrossrefPubMedGoogle Scholar
  • 19 Direskeneli H, Hasan A, Shinnick T et al. Recognition of B-cell epitopes of the 65 kDa HSP in Behcet’s disease. Scandinavian Journal of Immunology 1996; 43: 464-471
    CrossrefPubMedGoogle Scholar
  • 20 Baskan EB, Yilmaz E, Saricaoglu H et al. Detection of parvovirus B19 DNA in the lesional skin of patients with Behcet’s disease. Clinical and Experimental Dermatology 2007; 32: 186-190
    CrossrefPubMedGoogle Scholar
  • 21 Apan TZ, Gursel R, Dolgun A. Increased seropositivity of Helicobacter pylori cytotoxin-associated gene-A in Behcet’s disease. Clinical Rheumatology 2007; 26: 885-889
    CrossrefPubMedGoogle Scholar
  • 22 Mumcu G, Inanc N, Aydin SZ et al. Association of salivary S. mutans colonisation and mannose-binding lectin deficiency with gender in Behcet’s disease. Clinical and Experimental Rheumatology 2009; 27: S32-S36
    PubMedGoogle Scholar
  • 23 Hatemi G, Seyahi E, Fresko I et al. Behcet’s syndrome: a critical digest of the 2013–2014 literature. Clinical and Experimental Rheumatology 2014; 32: S112-S122
    PubMedGoogle Scholar
  • 24 Chambers JC, Haskard DO, Kooner JS. Vascular endothelial function and oxidative stress mechanisms in patients with Behcet’s syndrome. Journal of the American College of Cardiology 2001; 37: 517-520
    CrossrefPubMedGoogle Scholar
  • 25 Inanc N, Mumcu G, Birtas E et al. Serum mannose-binding lectin levels are decreased in behcet’s disease and associated with disease severity. The Journal of Rheumatology 2005; 32: 287-291
    PubMedGoogle Scholar
  • 26 Yavuz S, Elbir Y, Tulunay A et al. Differential expression of toll-like receptor 6 on granulocytes and monocytes implicates the role of microorganisms in Behcet's disease etiopathogenesis. Rheumatology international 2008; 28: 401-406
    CrossrefPubMedGoogle Scholar
  • 27 Kural-Seyahi E, Fresko I, Seyahi N et al. The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine 2003; 82: 60-76
    CrossrefPubMedGoogle Scholar
  • 28 Isene R, Bernklev T, Hoie O et al. Extraintestinal manifestations in Crohn’s disease and ulcerative colitis: results from a prospective, population-based European inception cohort. Scandinavian Journal of Gastroenterology 2015; 50: 300-305
    CrossrefPubMedGoogle Scholar
  • 29 Jung YS, Cheon JH, Park SJ et al. Long-term clinical outcomes of Crohn’s disease and intestinal Behcet’s disease. Inflammatory Bowel Diseases 2013; 19: 99-105
    CrossrefPubMedGoogle Scholar
  • 30 Niccoli L, Nannini C, Benucci M et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet’s disease: a 24-month follow-up study. Rheumatology 2007; 46: 1161-1164
    CrossrefPubMedGoogle Scholar
  • 31 Yim SM, Kim DH, Lee HJ et al. Mucosal healing predicts the long-term prognosis of intestinal Behcet’s disease. Digestive Diseases and Sciences 2014; 59: 2529-2535
    CrossrefPubMedGoogle Scholar
  • 32 Schnitzler F, Fidder H, Ferrante M et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease. Inflammatory Bowel Diseases 2009; 15: 1295-1301
    CrossrefPubMedGoogle Scholar
  • 33 Colombel JF, Rutgeerts P, Reinisch W et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011; 141: 1194-1201
    CrossrefPubMedGoogle Scholar
  • 34 Tolia V, Abdullah A, Thirumoorthi MC et al. A case of Behcet’s disease with intestinal involvement due to Crohn's disease. The American Journal of Gastroenterology 1989; 84: 322-325
    PubMedGoogle Scholar
  • 35 Hamuryudan V, Mat C, Saip S et al. Thalidomide in the Treatment of the Mucocutaneous Lesions of the Behcet Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Ann Intern Med 1998; 128: 443-450
    CrossrefPubMedGoogle Scholar